Publication:
How the Addition of Hormones Improves Outcome: Hormone Therapy and Chemotherapy

dc.contributor.authorWachira Kochakarnen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-07-24T03:54:42Z
dc.date.available2018-07-24T03:54:42Z
dc.date.issued2004-01-01en_US
dc.description.abstractChemotherapy alone for the treatment of hormone-resistant prostate cancer is associated with very poor objective response rates of less than 10%. No single agent or regimen has thus far shown a consistent impact on survival. As a result, there is no standard regimen and new agents and combinations are continually being investigated. In theory, it may be beneficial to start chemotherapy earlier in the disease, while the patient is still responding to hormonal therapy but when their PSA is already starting to rise. © 2004 Elsevier B.V. All rights reserved.en_US
dc.identifier.citationEuropean Urology, Supplements. Vol.3, No.1 (2004), 37-39en_US
dc.identifier.doi10.1016/j.eursup.2003.12.009en_US
dc.identifier.issn15699056en_US
dc.identifier.other2-s2.0-1042289549en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/21746
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=1042289549&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleHow the Addition of Hormones Improves Outcome: Hormone Therapy and Chemotherapyen_US
dc.typeConference Paperen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=1042289549&origin=inwarden_US

Files

Collections